LOOK TO
PUSH RET
BACK

with GAVRETO, the only once-daily therapy designed to selectively target RET1

NCCN Recommended

Pralsetinib is an NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)–recommended treatment option for certain patients with RET+ mNSCLC and RET+ advanced or metastatic thyroid carcinoma2,3*†

*See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC and thyroid carcinoma for detailed recommendations, including other preferred treatment options. For select patients with recurrent/persistent locoregional or distantly metastatic RET mutation-positive medullary thyroid carcinoma; for structurally persistent/recurrent locoregional or distantly metastatic RET fusion-positive differentiated thyroid cancer not amenable to RAI therapy; and for metastatic RET fusion-positive anaplastic thyroid carcinoma. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. mNSCLC=metastatic non–small cell lung cancer; RECIST=Response Evaluation Criteria in Solid Tumors; RET=rearranged during transfection.